These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 20975102)
21. Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. Jadvar H; Desai B; Ji L; Conti PS; Dorff TB; Groshen SG; Pinski JK; Quinn DI J Nucl Med; 2013 Aug; 54(8):1195-201. PubMed ID: 23785174 [TBL] [Abstract][Full Text] [Related]
22. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330 [TBL] [Abstract][Full Text] [Related]
23. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635 [TBL] [Abstract][Full Text] [Related]
24. Prognostic value of [ Li A; Shen K; Ji Y; Zhang W; Liu B; Su R; Zhou X; Dong L; Zhu Y; Dong B; Pan J; Wang Q; Xue W Ann Med; 2024 Dec; 56(1):2411017. PubMed ID: 39392016 [TBL] [Abstract][Full Text] [Related]
25. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Specht JM; Tam SL; Kurland BF; Gralow JR; Livingston RB; Linden HM; Ellis GK; Schubert EK; Dunnwald LK; Mankoff DA Breast Cancer Res Treat; 2007 Sep; 105(1):87-94. PubMed ID: 17268819 [TBL] [Abstract][Full Text] [Related]
26. Complimentary role of FDG-PET imaging and skeletal scintigraphy in the evaluation of patients of prostate carcinoma. Tiwari BP; Jangra S; Nair N; Tongaonkar HB; Basu S Indian J Cancer; 2010; 47(4):385-90. PubMed ID: 21131750 [TBL] [Abstract][Full Text] [Related]
27. Comparison of 18F fluoride PET/CT and 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma. Chakraborty D; Bhattacharya A; Mete UK; Mittal BR Clin Nucl Med; 2013 Aug; 38(8):616-21. PubMed ID: 23603596 [TBL] [Abstract][Full Text] [Related]
28. Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases. Iagaru A; Young P; Mittra E; Dick DW; Herfkens R; Gambhir SS Clin Nucl Med; 2013 Jul; 38(7):e290-6. PubMed ID: 23455520 [TBL] [Abstract][Full Text] [Related]
29. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan? Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321 [TBL] [Abstract][Full Text] [Related]
30. Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer. Chen B; Wei P; Macapinlac HA; Lu Y Nucl Med Commun; 2019 Sep; 40(9):940-946. PubMed ID: 31343613 [TBL] [Abstract][Full Text] [Related]
31. Comparison of the diagnostic accuracy of 99 m-Tc-MDP bone scintigraphy and 18 F-FDG PET/CT for the detection of skeletal metastases. Chang CY; Gill CM; Joseph Simeone F; Taneja AK; Huang AJ; Torriani M; Bredella MA Acta Radiol; 2016 Jan; 57(1):58-65. PubMed ID: 25533313 [TBL] [Abstract][Full Text] [Related]
32. Increased Prostate Cancer Glucose Metabolism Detected by Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897 [TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma. Franzius C; Bielack S; Flege S; Sciuk J; Jürgens H; Schober O J Nucl Med; 2002 Aug; 43(8):1012-7. PubMed ID: 12163625 [TBL] [Abstract][Full Text] [Related]
34. Earlier detection of bone metastases from pleomorphic liposarcoma in a pediatric patient by FDG PET/CT than planar 99mTc MDP bone scan. Yang J; Codreanu I; Servaes S; Zhuang H Clin Nucl Med; 2012 May; 37(5):e104-7. PubMed ID: 22475918 [TBL] [Abstract][Full Text] [Related]
36. Prospective Study of Serial Peterson LM; O'Sullivan J; Wu QV; Novakova-Jiresova A; Jenkins I; Lee JH; Shields A; Montgomery S; Linden HM; Gralow J; Gadi VK; Muzi M; Kinahan P; Mankoff D; Specht JM J Nucl Med; 2018 Dec; 59(12):1823-1830. PubMed ID: 29748233 [TBL] [Abstract][Full Text] [Related]
37. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. Pryma DA; Schöder H; Gönen M; Robbins RJ; Larson SM; Yeung HW J Nucl Med; 2006 Aug; 47(8):1260-6. PubMed ID: 16883003 [TBL] [Abstract][Full Text] [Related]
38. Diagnostic accuracy of bone metastases detection in cancer patients: comparison between bone scintigraphy and whole-body FDG-PET. Fujimoto R; Higashi T; Nakamoto Y; Hara T; Lyshchik A; Ishizu K; Kawashima H; Kawase S; Fujita T; Saga T; Togashi K Ann Nucl Med; 2006 Jul; 20(6):399-408. PubMed ID: 16922468 [TBL] [Abstract][Full Text] [Related]
39. 99mTc-MDP bone scintigraphy and 18F-FDG positron emission tomography in lung and prostate cancer patients: different affinity between lytic and sclerotic bone metastases. Garcia JR; Simo M; Perez G; Soler M; Lopez S; Setoain X; Lomeña F Eur J Nucl Med Mol Imaging; 2003 Dec; 30(12):1714. PubMed ID: 14625662 [No Abstract] [Full Text] [Related]
40. 99mTc-MDP Bone Scan and 18F-FDG PET/CT Imaging of Multiple Extraskeletal Osteosarcomas. Sun ZK; Shen CT; Qiu ZL; Luo QY Clin Nucl Med; 2018 Nov; 43(11):e412-e413. PubMed ID: 30106862 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]